Lyra Therapeutics, Inc.

NasdaqGM:LYRA 주식 보고서

시가총액: US$16.9m

Lyra Therapeutics 관리

관리 기준 확인 2/4

We currently do not have sufficient information about the CEO.

주요 정보

Maria Palasis

최고 경영자

US$1.8m

총 보상

CEO 급여 비율32.7%
CEO 임기9.8yrs
CEO 소유권n/a
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간4.1yrs

최근 관리 업데이트

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

CEO 보상 분석

Maria Palasis 의 보수는 Lyra Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

보상 대 시장: Maria's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD655.65K).

보상과 수익: Maria's compensation has increased whilst the company is unprofitable.

CEO

Maria Palasis (59 yo)

9.8yrs

테뉴어

US$1,785,375

보상

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

리더십 팀

이름위치테뉴어보상소유권
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79m데이터 없음
Carmichael Roberts
Co-Founderno data데이터 없음데이터 없음
Jason Cavalier
CFO, Treasurer & Secretary3.2yrsUS$1.07m데이터 없음
Ray Knox
Vice President of Operationsno data데이터 없음데이터 없음
Ronan O'Brien
Chief Legal Officer1.1yrs데이터 없음데이터 없음
Vineeta Belanger
Senior Vice President of Clinical Affairsno data데이터 없음데이터 없음
Robert Richard
Senior Vice President of Technical Operations1.8yrsUS$666.79k데이터 없음
Robert Kern
Chief Clinical Advisor3.8yrs데이터 없음데이터 없음
Gloria Cosgrove
Senior Vice President of Quality1.8yrs데이터 없음데이터 없음
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrs데이터 없음데이터 없음
Elazer Edelman
VP of Finance & Riskno data데이터 없음데이터 없음

2.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: LYRA's management team is considered experienced (2.3 years average tenure).

이사회 구성원

이름위치테뉴어보상소유권
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79m데이터 없음
James Tobin
Lead Independent Director2.7yrsUS$152.31k0%
$ 0
W. Smith
Independent Director5yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4.1yrsUS$333.93k데이터 없음
C. Merrifield
Independent Director5.2yrsUS$113.06k0.017%
$ 2.9k
Robert Langer
Member of Scientific Advisory Board4.1yrsUS$19.36k데이터 없음
Michael Dake
Member of Medical Advisory Boardno data데이터 없음데이터 없음
William Gray
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Mahmood Razavi
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Gary Ansel
Member of Medical Advisory Boardno data데이터 없음데이터 없음
I. Baumgartner
Member of Medical Advisory Boardno data데이터 없음데이터 없음

4.1yrs

평균 재임 기간

73yo

평균 연령

경험이 풍부한 이사회: LYRA's board of directors are considered experienced (4.1 years average tenure).